Search Results

There are 4117 results for: content related to: Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C

VIEW

  1. 1 - 20
  2. 21 - 40
  3. 41 - 60
  4. 61 - 80
  5. Next >
  1. Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 31, Issue 10, October 2011, Pages: 951–974, Olga M. Klibanov, Shannon H. Williams, Lisa S. Smith, Jacqueline L. Olin and Stephen B. Vickery

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.31.10.951

  2. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

    Journal of Viral Hepatitis

    Volume 19, Issue s2, May 2012, Pages: 1–26, I. M. Jacobson, J.-M. Pawlotsky, N. H. Afdhal, G. M. Dusheiko, X. Forns, D. M. Jensen, F. Poordad and J. Schulz

    Article first published online : 8 MAR 2012, DOI: 10.1111/j.1365-2893.2012.01590.x

  3. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial

    Hepatology

    Volume 56, Issue 6, December 2012, Pages: 2106–2115, Sandra De Meyer, Inge Dierynck, Anne Ghys, Maria Beumont, Bjorn Daems, Ben Van Baelen, James C. Sullivan, Douglas J. Bartels, Tara L. Kieffer, Stefan Zeuzem and Gaston Picchio

    Article first published online : 4 DEC 2012, DOI: 10.1002/hep.25962

  4. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes

    Journal of Viral Hepatitis

    Volume 20, Issue 6, June 2013, Pages: 395–403, S. De Meyer, A. Ghys, G. R. Foster, M. Beumont, B. Van Baelen, T.-I. Lin, I. Dierynck, H. Ceulemans and G. Picchio

    Article first published online : 10 JAN 2013, DOI: 10.1111/jvh.12046

  5. You have full text access to this OnlineOpen article
    Review article: specifically targeted anti-viral therapy for hepatitis C – a new era in therapy

    Alimentary Pharmacology & Therapeutics

    Volume 32, Issue 1, July 2010, Pages: 14–28, C. M. Lange, C. Sarrazin and S. Zeuzem

    Article first published online : 31 MAR 2010, DOI: 10.1111/j.1365-2036.2010.04317.x

  6. You have full text access to this OnlineOpen article
    Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection

    Journal of Viral Hepatitis

    Volume 19, Issue 2, February 2012, Pages: e112–e119, I. Yamada, F. Suzuki, N. Kamiya, K. Aoki, Y. Sakurai, M. Kano, H. Matsui and H. Kumada

    Article first published online : 7 OCT 2011, DOI: 10.1111/j.1365-2893.2011.01514.x

  7. Effect of Telaprevir on the Pharmacokinetics of Midazolam and Digoxin

    The Journal of Clinical Pharmacology

    Volume 52, Issue 10, October 2012, Pages: 1566–1573, Dr Varun Garg, Dr Gurudatt Chandorkar, Dr H. Frank Farmer, Dr Frances Smith, Dr Katia Alves and Dr Rolf P. G. van Heeswijk

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270011419850

  8. AASLD Abstracts

    Hepatology

    Volume 56, Issue S1, October 2012, Pages: 191A–1144A,

    Article first published online : 1 OCT 2012, DOI: 10.1002/hep.26040

  9. You have full text access to this OnlineOpen article
    A glimpse of future hepatitis C virus treatment paradigms

    Hepatology

    Volume 51, Issue 2, February 2010, Pages: 707–710, Norah Terrault and Mandana Khalili

    Article first published online : 26 JAN 2010, DOI: 10.1002/hep.23523

  10. You have full text access to this OnlineOpen article
    Drug therapy: Telaprevir

    Hepatology

    Volume 54, Issue 4, October 2011, Pages: 1463–1469, Michael D. Leise, W. Ray Kim, Katherine M. Canterbury and John J. Poterucha

    Article first published online : 27 SEP 2011, DOI: 10.1002/hep.24660

  11. You have free access to this content
    Telaprevir user's guide

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 17–25, Ann Marie Liapakis and Ira Jacobson

    Article first published online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02708.x

  12. You have full text access to this OnlineOpen article
    Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

    Journal of Viral Hepatitis

    Volume 19, Issue 2, February 2012, Pages: e134–e142, N. Hayashi, T. Okanoue, H. Tsubouchi, J. Toyota, K. Chayama and H. Kumada

    Article first published online : 8 NOV 2011, DOI: 10.1111/j.1365-2893.2011.01528.x

  13. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers

    British Journal of Clinical Pharmacology

    Volume 75, Issue 2, February 2013, Pages: 431–439, Varun Garg, Gurudatt Chandorkar, Yijun Yang, Nathalie Adda, Lindsay McNair, Katia Alves, Frances Smith and Rolf P. G. van Heeswijk

    Article first published online : 10 JAN 2013, DOI: 10.1111/j.1365-2125.2012.04345.x

  14. You have full text access to this OnlineOpen article
    Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response

    Hepatology

    Volume 54, Issue 5, November 2011, Pages: 1538–1546, Andrew J. Muir, Fred F. Poordad, John G. McHutchison, Mitchell L. Shiffman, Thomas Berg, Peter Ferenci, E. Jenny Heathcote, Jean-Michel Pawlotsky, Stefan Zeuzem, Henk W. Reesink, Geoffrey Dusheiko, Emily C. Martin, Shelley George, Robert S. Kauffman and Nathalie Adda

    Article first published online : 24 AUG 2011, DOI: 10.1002/hep.24549

  15. You have free access to this content
    An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

    Hepatology

    Volume 54, Issue 4, October 2011, Pages: 1433–1444, Marc G. Ghany, David R. Nelson, Doris B. Strader, David L. Thomas and Leonard B. Seeff

    Article first published online : 26 SEP 2011, DOI: 10.1002/hep.24641

  16. You have free access to this content
    Optimal treatment with telaprevir for chronic HCV infection

    Liver International

    Volume 33, Issue s1, February 2013, Pages: 3–13, Arun B. Jesudian and Ira M. Jacobson

    Article first published online : 3 JAN 2013, DOI: 10.1111/liv.12079

  17. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1

    Journal of Medical Virology

    Volume 85, Issue 6, June 2013, Pages: 1028–1036, Norio Akuta, Fumitaka Suzuki, Yuya Seko, Yusuke Kawamura, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Tasuku Hara, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda and Hiromitsu Kumada

    Article first published online : 12 APR 2013, DOI: 10.1002/jmv.23579

  18. The Pharmacokinetic Interaction Between an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone and the HCV Protease Inhibitor Telaprevir

    The Journal of Clinical Pharmacology

    Volume 52, Issue 10, October 2012, Pages: 1574–1583, Dr Varun Garg, Dr Rolf van Heeswijk, Dr Yijun Yang, Dr Robert Kauffman, Dr Frances Smith and Dr Nathalie Adda

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270011419855

  19. You have full text access to this OnlineOpen article
    Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients

    Hepatology

    Volume 50, Issue 6, December 2009, Pages: 1709–1718, Simone Susser, Christoph Welsch, Yalan Wang, Markus Zettler, Francisco S. Domingues, Ursula Karey, Eric Hughes, Robert Ralston, Xiao Tong, Eva Herrmann, Stefan Zeuzem and Christoph Sarrazin

    Article first published online : 4 AUG 2009, DOI: 10.1002/hep.23192

  20. You have free access to this content
    UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients

    Alimentary Pharmacology & Therapeutics

    Volume 35, Issue 6, March 2012, Pages: 647–662, P. Ramachandran, A. Fraser, K. Agarwal, A. Austin, A. Brown, G. R. Foster, R. Fox, P. C. Hayes, C. Leen, P. R. Mills, D. J. Mutimer, S. D. Ryder and J. F. Dillon

    Article first published online : 1 FEB 2012, DOI: 10.1111/j.1365-2036.2012.04992.x

VIEW

  1. 1 - 20
  2. 21 - 40
  3. 41 - 60
  4. 61 - 80
  5. Next >